Splenectomy in ITP: we keep removing a healthy functional organ.

about

Splenectomy in ITP: we keep removing a healthy functional organ.

Item

http://www.wikidata.org/entity/Q48088532

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Splenectomy in ITP: we keep removing a healthy functional organ.

@en

Splenectomy in ITP: we keep removing a healthy functional organ.

@nl

type

Item

label

Splenectomy in ITP: we keep removing a healthy functional organ.

@en

Splenectomy in ITP: we keep removing a healthy functional organ.

@nl

prefLabel

Splenectomy in ITP: we keep removing a healthy functional organ.

@en

Splenectomy in ITP: we keep removing a healthy functional organ.

@nl

P1476

Splenectomy in ITP: we keep removing a healthy functional organ.

@en

P2093

Eduardo Anguita

http://www.w3.org/2001/XMLSchema#string

F Javier Martín-Sánchez

http://www.w3.org/2001/XMLSchema#string

Francisco Javier Candel

http://www.w3.org/2001/XMLSchema#string

Juan González-Del Castillo

http://www.w3.org/2001/XMLSchema#string

P2860

The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.

Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia.

ITP and international guidelines: what do we know, what do we need?

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.

Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.

Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.

Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines.

Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up

P304

1911-1912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-016-2778-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eduardo Anguita

Francisco Javier Candel

J Gonzalez-Castillo

Francisco Javier Martín-Sánchez

P577

2016-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27577110

http://www.w3.org/2001/XMLSchema#string